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The production of high-affinity antibodies by B cells is essential for pathogen clearance.
Antibody affinity for antigen is increased through the affinity maturation in germinal centers
(GCs). This is an iterative process in which B cells cycle between proliferation coupled with
the acquisition of mutations and antigen-based positive selection, resulting in retention of
the highest-affinity B cell clones. The posttranscriptional regulator microRNA-155 (miR-155)
is critical for efficient affinity maturation and the maintenance of the GCs; however, the
cellular and molecular mechanism by which miR-155 regulates GC responses is not well
understood. Here, we utilized a miR-155 reporter mouse strain and showed that miR-155 is
coexpressed with the proto-oncogene encoding c-MYC in positively selected B cells.
Functionally, miR-155 protected positively selected c-MYC+ B cells from apoptosis,
allowing clonal expansion of this population, providing an explanation as to why Mir155
deletion impairs affinity maturation and promotes the premature collapse of GCs. We
determined that miR-155 directly inhibits the Jumonji family member JARID2, which
enhances B cell apoptosis when overexpressed, and thereby promotes GC B cell survival.
Our findings also suggest that there is cooperation between c-MYC and miR-155 during the
normal GC response, a cooperation that may explain how c-MYC and miR-155 can
collaboratively function as oncogenes.
Research Article Immunology
Find the latest version:
http://jci.me/82914
The Journal of Clinical Investigation   R e s e a R c h  a R t i c l e
3 7 7jci.org   Volume 126   Number 1   January 2016
Introduction
Germinal centers (GCs) form in B cell follicles of secondary lym-
phoid organs upon extensive proliferation of antigen-activated 
B cells that respond to T cell help. They are essential for the pro-
duction of plasma cells that secrete high-affinity antibodies and 
high-affinity memory B cells. Despite their importance for vac-
cine- and infection-induced protection (1, 2), there is limited 
understanding of the molecular program that leads to the selec-
tion of high-affinity B cell clones within the GC.
Affinity maturation is the result of somatic hypermutation (SHM) 
of the B cell receptor (BCR) genes during intensive B cell division in 
the dark zone (DZ) (3), followed by rounds of affinity-based selection 
in the light zone (LZ), where B cells are either positively selected or 
die (4). This selection process is considered to be dependent on the 
affinity of the newly mutated BCR. Positively selected GC B cells can 
migrate back to the DZ, where they proliferate and undergo further 
SHM. This bidirectional interzonal migration cycle was postulated 
in the cyclic reentry model (5–7), and it is believed to be essential for 
efficient affinity maturation (4). Ultimately, positively selected B cells 
differentiate into memory B cells or plasma cells and exit the GC.
At the molecular level, the master regulator of GCs, BCL6, is 
upregulated in DZ B cells and represses genes involved in cell cycle 
arrest, the DNA damage response, and plasma cell differentiation 
(8). This allows SHM to take place, which requires high expres-
sion of AID in DZ B cells (9). As DZ B cells migrate toward the LZ, 
BCL6 expression is downregulated and B cells become dependent 
on extrinsic signals arising from interactions with antigen, follicu-
lar DCs, and T cells. As a result of such signaling events, a fraction 
of LZ B cells is positively selected. Recent studies have shown that 
c-MYC is expressed in those positively selected LZ B cells and is a 
critical regulator in GC maintenance (10, 11).
Among the genes repressed by BCL6 is the microRNA-155 (miR-
155) (8), a well-established regulator of activated B cells (8, 12–15). 
Despite the known role for miR-155 in regulating the GC response, 
the mechanisms by which it acts are only beginning to be understood. 
It has been suggested that BCL6, by inhibiting miR-155 in DZ B cells, 
positively regulates the expression of miR-155 target genes (8). How-
ever, it remains to be learned what cellular processes and molecular 
targets miR-155 regulates while it is expressed in GC B cells.
Here, we uncover a dynamic regulation of miR-155, which is 
expressed in a small subset of LZ B cells. The miR-155+ subset is 
enriched in cycling cells and coexpresses c-MYC, demonstrating 
that miR-155 expression is linked to positively selected B cells. 
Functionally, we observed that expression of miR-155 protects 
c-MYC+ LZ B cells from apoptosis and thus plays a critical role in 
the maintenance of the GC response and in affinity maturation. 
One of the molecular targets that miR-155 directly inhibits is 
JARID2, whose overexpression promotes apoptosis of LZ B cells. 
Overall, our results reveal a mechanism of affinity selection by 
functionally linking c-MYC and miR-155.
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(Figure 1A, right). Immunohistological analysis confirmed these 
results and further revealed that B cell migration was not altered 
by miR-155 deficiency (Figure 1B). These results indicate that 
miR-155 is required to maintain the GC response.
Cycling LZ B cells express high levels of miR-155. Having estab-
lished that miR-155 is required for the maintenance of GC B cells 
in a B cell–intrinsic manner, we next assessed its expression pat-
tern to understand where it exerts its function in the GC response. 
To identify miR-155 expressing cells, we used the miR-155–LacZ 
reporter strain, which replaces the Mir155 coding sequence with 
a LacZ cassette, producing a nonfunctional allele (13). The tran-
scriptional activity of the Mir155 gene is monitored by detecting 
LacZ activity. If transcription is coupled to processing, LacZ activ-
ity may mirror mature miR-155 abundance. We tested whether 
LacZ expression was associated with miR-155 expression in sin-
gle cell–sorted GC B cells. We adoptively transferred SWHEL Mir-
155LacZ/+ B cells into CD45.1+ congenic mice and injected them with 
HEL3X-SRBC. Five days later, we sorted GC B cells as DZ or LZ 
Results
miR-155 deficiency decreases the number of DZ and LZ B cells. To 
further understand the defects in GC responses caused by miR-
155 deficiency in a B cell–intrinsic manner, we utilized the SWHEL 
mouse model. SWHEL mice have the heavy and light chains of 
the HyHEL10 BCR that recognizes hen egg lysozyme (HEL) 
knocked in to the endogenous Bcr locus. This enables tracking 
of class-switch recombination and SHM of the transgenic BCR 
during the GC response (16). SWHEL Mir155+/+ or SWHEL Mir155–/– 
B cells were adoptively transferred into CD45.1+ congenic recip-
ients, which were immunized with HEL3X, a HEL mutant with a 
Ka of approximately 1.5 × 106 M–1 affinity for HyHEL10 (17, 18), 
coupled to sheep red blood cells (SRBC). HEL+ GC B cells were 
gated as described in Figure 1A (left). We observed the peak of 
DZ B cells at day 5 and the peak of LZ B cells at day 6 (Figure 
1A, right). Although the absence of miR-155 had no effect on the 
number of GC B cells until day 4, cell numbers were severely 
reduced: ~6-fold at day 5, ~19-fold at day 6, and ~28-fold at day 7 
Figure 1. miR-155 in B cells is required 
for the maintenance of the GC response. 
SWHEL Mir155
+/+ or SWHEL Mir155
–/– donor 
B cells were adoptively transferred into 
CD45.1+ congenic recipient mice that were 
then injected with HEL3X-SRBC. Spleen 
cells from these mice were analyzed by 
flow cytometry at the indicated days. (A)
The gating strategy and experimental 
design are shown (left). The FACS plot 
analyzing SWHEL Mir155
+/+ donor cell 
at day 4 is shown as an example. The 
number of donor-derived (CD45.1–CD45.2+) 
HEL-specific GC B cells was calculated 
based on the proportion of cells stained as 
CD38loCD95+ and HEL-binders and further 
divided as CXCR4hiCD86lo for DZ B cells 
and CXCR4loCD86hi for LZ B cells (right). 
Data represent 1 out of 3 independent 
experiments. The mean ± SEM is shown 
(SWHEL Mir155
+/+; d4, n = 6; d5, n = 4; d6, 
n=5; and d7, n = 4. SWHEL Mir155
–/–; d4, 
n = 6; d5, n = 4; d6, n = 8; and d7, n = 4). 
Two-tailed unpaired t test, SWHEL Mir155
+/+ 
LZ vs. SWHEL Mir155
–/– LZ, at d5, d6, and 
d7. *P < 0.05, **P < 0.005, ***P < 0.0005, 
and the same for SWHEL Mir155
+/+ DZ vs. 
SWHEL Mir155
–/– DZ. (B) Splenic sections 
containing adoptively transferred B cells 
of the indicated genotype were stained for 
IgD in red, CD3 in blue, and HEL binding in 
green at d3.5 or d5. Arrows indicate GCs. 
Scale bar: 50 μm.
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To decipher the directionality of the interzonal DZ-LZ cycling, 
we looked at the proportions of S and G2/M cells in the 4 different 
subsets. In the LZ, a higher proportion of LacZ+ cells than LacZ– 
cells were in S-phase, suggesting that the LacZ+ cells are enriched 
in positively selected cells in transit to the DZ. As the DZ LacZ– cells 
contained a decreased proportion of S- and G2/M-phases compared 
with the vigorously proliferating DZ LacZ+ cells (Figure 3A), we con-
cluded that they were completing their rounds of cell division. Col-
lectively, our working model is that cycling cells in the LZ express 
high levels of miR-155 (LZ LacZ+) and they migrate to the DZ, where 
they proliferate actively (DZ LacZ+) and start downregulating miR-
155 expression. They then start to exit the cell cycle (DZ LacZ–) and, 
upon completion of the cell cycle, they return to the LZ (LZ LacZ–).
To substantiate this model, we next looked at the expression pat-
tern of some key GC molecules. We measured activation-induced 
cytidine deaminase (Aicda) transcripts because this gene is known to 
be highly expressed in DZ B cells (19) in order to enable SHM. Aicda 
expression was highest in the DZ LacZ– subset (Figure 3D). Cells in 
this subset are dividing but are already past their most active stage 
of proliferation (Figure 3A), which may allow them to increase the 
number of BCR mutations before they return to the LZ. Elevated 
expression of Prdm1 was observed in the DZ LacZ+ subset (Figure 
3D), in agreement with the findings showing that GC B cells differ-
entiate into plasma cells and leave GCs through the DZ (20). We next 
further divided by LacZ status, generating 4 subsets: DZ LacZ–, 
DZ LacZ+, LZ LacZ–, and LZ LacZ+ (Figure 2A). LacZ+ cells tend 
to express higher levels of miR-155 than LacZ– cells (Figure 2B), 
although the discrimination is much clear for LZ B cells. This is 
likely due to the lower level of miR-155 in DZ B cells than LZ B 
cells. These results indicate that miR-155 is mainly expressed at 
the highest levels in a fraction of LZ B cells.
We next assessed the association between cells expressing high 
levels of miR-155 and proliferation. According to the cyclic reentry 
GC model, positively selected B cells start cell cycling in the LZ and 
then either differentiate into memory/plasma cells and exit GC or 
reenter the DZ and actively proliferate. Thus, the cell cycle status of 
miR-155+ LZ B cells may allow us to assess the role being played by 
miR-155. In agreement with published data (4), we found that the 
DZ is the major site for proliferation (Figure 3A). Hardly any LZ B 
cell were in G2/M-phase, but LZ LacZ+, which express the greatest 
amount of miR-155, had a higher proportion of S-phase cells (12.1% 
± 0.95%) than LZ LacZ– cells (5.47% ± 1.7%); Figure 3A). In the 
DZ, LacZ positivity also defined a highly proliferative subset with 
a consistent increase in size (Figure 3, A and B). Interestingly, S and 
G2/M cells were clustered at the border of the DZ and LZ regions 
delineated in the FACS plots on the basis of CXCR4 and CD86 
(Figure 3C). Altogether, these results indicate that GC B cells are a 
more heterogeneous population than originally thought.
Figure 2. A subset of LZ B cells highly 
expresses miR-155. SWHEL Mir155LacZ/+ 
B cells were adoptively transferred into 
CD45.1+ congenic recipient mice, which 
were then injected with HEL3X-SRBC 
and analyzed after 5 days. (A) GC B cell 
gating strategy to define 4 GC subsets. 
First, DZ and LZ B cells were identified 
as explained in Figure 1 and then LacZ 
activity was visualized with fluorescein 
di-V-galactoside (FDG). The percent-
ages of LacZ+ cells are shown (mean ± 
SEM of independent sorting and flow 
cytometric analyses [n = 16]). (B) The 
4 subsets of GC B cells indicated in A 
were single cell sorted from 4 mice and 
analyzed for the expression of miR-155 
by qPCR using U6 for normalization 
(DZ LacZ–, n = 45; DZ LacZ+, n = 54; DZ 
LacZ–, n = 52; DZ LacZ+, n = 52). His-
tograms show the distribution of cells 
on the basis of miR-155 expression in 
log-transformed arbitrary units. Bars 
are nudged to prevent overlapping. 
Background level was established by 
assessing the expression of miR-155 in 
Mir155–/– GC B cells, which was negligi-
ble (not shown). Also, miR-155 in naive 
B cells was very low (not shown).
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with this article; doi:10.1172/JCI82914DS1). Although these analy-
ses were carried out at day 5, highest expression of both miR-155 and 
c-MYC in LZ LacZ+ was also observed at day 4 (Supplemental Figure 
2, A and B). Together, these results suggest that c-MYC and miR-155 
are coexpressed in positively selected LZ B cells.
looked at Myc expression because it is upregulated in proliferative 
positively selected LZ B cells (10, 11). As expected, Myc expression 
was low in DZ B cells, and its greatest expression was detected in 
the LZ LacZ+ subset, which is high in miR-155 (Figure 2B, Figure 3D, 
and Supplemental Figure 2A; supplemental material available online 
Figure 3. miR-155 expression is associated with cell cycle progression of GC B cells. SWHEL Mir155LacZ/+ B cells were adoptively transferred into CD45.1+ congenic 
recipient mice, which were then injected with HEL3X-SRBC and analyzed after 5 days. LacZ reporter staining is incompatible with permeabilization and, there-
fore, cells were sorted first using the strategy explained in Figure 2A. Subsequently, cell cycle was analyzed in the 4 subsets of GC B cells by DAPI staining. The 
mean of the indicated fraction ± SEM from 3 independent experiments is shown. (A) HEL-binding vs. DAPI. (B) Forward scatter (FSC) vs. side scatter (SSC). 
(C) S-phase and G2/M-phase B cells for each of the sorted subsets were gated as shown in A. The upper panel shows the CXCR4/CD86 distribution of cells in 
S-phase cells (black dots) superimposed on DZ cells (pink) or LZ cells (light blue) of the indicated subset. The lower panel is similar to the upper panel, except 
that G2/M-phase cells (black) are shown. The percentage of black dots over total cell per gate is shown. A representative FACS plot of the indicated subset out 
of 3 independent experiments is shown (A–C). (D) The indicated subsets were sorted at day 5 after HEL3x-SRBC immunization. Aicda, Prdm1, and Myc tran-
scripts levels were analyzed by qPCR and normalized by Hprt. Naive follicular B cells (Fo-B) were sorted as B220+AA4.1–CD21/35intCD23hi cells from 2 naive mice. 
The experiment shown is representative of 3 independent sorting experiments. In each experiment, cDNA was prepared from sorted cells after pooling 5–10 
mice. The mean ± SEM is shown. *P < 0.05, **P < 0.01, ***P < 0.001 using 1-way ANOVA followed by a Tukey’s multiple comparisons post-test.
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than LZ B cells. Consequently LZ B cells coexpressed c-MYC and 
miR-155 at its highest level (Figure 4B). To examine whether miR-
155 deficiency affected the expression of c-MYC, we compared the 
proportions of c-MYC+ GC B cells originating from adoptively trans-
ferred miR-155–sufficient and –deficient B cells. As shown in Figure 
4A, disruption of miR-155 did not affect the emergence of c-MYC+ 
LZ B cells. Thus, induction of c-MYC does not require miR-155.
Having established that c-MYC and miR-155 are mainly coex-
pressed, we then assessed whether the 2 molecules are function-
ally linked. We split GC B cells on the basis of c-MYC expression in 
combination with DZ and LZ delineation. Apoptosis was measured 
in miR-155–sufficient and –deficient subsets by AnnexinV staining, 
miR-155 provides survival signals to positively selected c-MYC+ LZ 
B cells. To characterize further the expression pattern of miR-155 and 
c-MYC in LZ B cells, we made use of Mycgfp/gfp reporter mice (21), 
which we crossed to SWHEL mice. After adoptive transfer of Mycgfp/gfp 
SWHEL B cells into CD45.1+ congenic mice followed by HEL3X-SRBC 
injection, we single cell–sorted c-MYC+ LZ, c-MYC– LZ, c-MYC+ DZ, 
and c-MYC– DZ B cells from these mice (Figure 4A) and measured 
the expression of miR-155 by quantitative PCR (qPCR). c-MYC+ cells 
expressed higher levels of miR-155 than c-MYC– cells, both in the 
DZ and the LZ, indicating that c-MYC is a strong predictor of miR-
155 expression (Figure 4B). In agreement with our previous analysis 
(Figure 2B), on average, DZ B cells expressed lower levels of miR-155 
Figure 4. miR-155 is coex-
pressed with c-MYC in a sub-
set of LZ B cells. Splenic B cells 
derived from Mycgfp/gfp SWHEL 
Mir155+/+ or Mycgfp/gfp SWHEL 
Mir155–/– mice were adop-
tively transferred into CD45.1+ 
congenic recipients, which 
were injected with HEL3X- 
SRBC. (A) Four days later, 
CD45.1–CD45.2+CD38loCD95+ 
HEL–specific donor-derived 
splenic GC B cells were gated 
as DZ or LZ and further divided 
based on GFP expression. The 
mean ± SEM from 2 indepen-
dent sorting experiments is 
shown (n = 6). (B) Four days 
after adoptive transfer of 
Mycgfp/gfp SWHEL Mir155
+/+ cells, 
DZ GFP–, DZ GFP+, LZ GFP–, 
and LZ GFP+ cells were single 
cell sorted according to the 
gates shown in A from 3 mice, 
and miR-155 expression was 
measured by qPCR using U6 
for normalization (DZ GFP–,  
n = 58; DZ GFP+, n = 50; LZ 
GFP–, n = 57; LZ GFP+,  
n = 46). Histograms show the 
distribution of cells on the 
basis of miR-155 expression 
in log-transformed arbitrary 
units. Bars are nudged to 
prevent overlapping. Back-
ground level was established 
by assessing the expression of 
miR-155 in Mir155–/– GC B cells.
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Figure 5. Positively selected LZ B cells gain antiapoptotic signals via miR-155. (A) Splenic B cells derived from Mycgfp/gfp SWHEL Mir155+/+ or Mycgfp/gfp 
SWHEL Mir155
–/– mice were adoptively transferred into CD45.1+ congenic recipients, which were injected with HEL3X-SRBC. Four days later, spleen cells 
from these mice were analyzed. The graph shows the percentage of AnnexinV+7-AAD– cells determined by flow cytometry in DZ and LZ B cells further 
divided on the basis of c-MYC expression. The mean ± SEM from 2 independent experiments is shown (Mycgfp/gfp Mir155+/+, n = 13; Mycgfp/gfp Mir155–/–, 
n = 13). *P < 0.05 using 1-way ANOVA followed by a Tukey’s multiple comparisons post-test. (B) SWHEL Mir155LacZ/+ or SWHEL Mir155LacZ/– B cells were 
adoptively transferred into CD45.1+ congenic recipients, which were injected with HEL3X-SRBC. Spleen cells from these mice were analyzed 5 days later. 
The graph shows the percentage of AnnexinV+7-AAD– cells determined by flow cytometry in DZ and LZ B cells further divided on the basis of LacZ pos-
itivity. The mean ± SEM from 2 independent experiments is shown (Mir155LacZ/+, n = 10; Mir155LacZ/–, n = 11). ***P < 0.001  using 1-way ANOVA followed 
by a Tukey’s multiple comparisons post-test. (C) Using the same HEL3X-SRBC injection as in B, IgG1+ donor–derived GC B cells were analyzed for their 
binding ability against HEL3X and HEL. Two independent experiments were performed, and the mean ± SEM of a representative experiment is shown 
(Mir155LacZ/+, n = 7; Mir155LacZ/–, n = 6). *P < 0.05, **P < 0.005 using 2-tailed unpaired t test (C). (D) Summary illustrations showing the role of miR-155 
in the GC response. The absence of miR-155 expression in positively selected c-MYC+ LZ B cells increase apoptosis in the population. Consequently, GC 
cellularity is decreased, and concomitantly, affinity maturation is abrogated.
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in combination with DAPI. We chose AnnexinV combined with 
DAPI staining to detect early apoptotic cells, as — unlike the detec-
tion of caspase 3 or cleaved poly-ADP ribose polymerase (PARP) 
— its measurement does not diminish the fluorescent signal for 
LacZ activity. We observed that c-MYC+ cells are more prone to 
apoptosis in the absence of miR-155 in both LZ and DZ, whereas 
c-MYC– Mir155–/– cells were similar to their Mir155+/+ counter-
parts (Figure 5A). To further validate these results, we measured 
apoptosis after delineating DZ and LZ B cells on the basis of LacZ 
expression in the presence or absence of miR-155. Then we gener-
ated miR-155–deficient mice in which one allele was replaced by a 
LacZ cassette (13) and the second allele was a previously described 
null allele (12), thus producing a Mir155LacZ/– genotype. Using the 
same adoptive transfer scheme described in previous sections, we 
observed similar levels of LacZ activity (based on the geometric 
mean fluorescence intensity [gMFI]) among sorted DZ and LZ GC 
B cells (Supplemental Figure 1A). In addition, LacZ activity was 
similar in DZ and LZ GC B cells derived from SWHEL Mir155LacZ/+ or 
SWHEL Mir155LacZ/– mice (Supplemental Figure 1B), indicating that 
transcriptional activity of the Mir155 promoter is not dependent 
on the expression of miR-155. The Mir155LacZ/– strain was then com-
pared with Mir155LacZ/+ and so allowed us to assess how B cells that 
would have expressed miR-155 (LacZ+) were affected by miR-155 
loss. As shown in Figure 5B, the subset of LZ B cells enriched in 
miR-155 expression in WT cells was the most susceptible to apop-
tosis in the absence of miR-155, followed by DZ LacZ+ cells. These 
Figure 6. GC phenotype due to miR-155 deficiency in B cells in silico. (A–D) Simulations of WT GC immunized with HEL3x (black lines and black-filled bars) 
or HEL (gray dashed lines) were used for validation of the reference simulations with in vivo experimental data (black open diamonds [A and B] and black 
open bars [C and D] for HEL3x, and gray open squares [A and B] for HEL). In silico miR-155 KO experiments were performed and compared with in vivo exper-
imental results (red open circles [A and B] and red open bar [C and D]) assuming various effects of miR-155 KO: reduced cell cycle speed (magenta lines [A 
and B] and magenta-filled bar [C and D]), reduced number of divisions during GC expansion (light-green lines [A and B] and light-green–filled bar [C and 
D]), and in addition, during GC selection phase (orange lines [A and B] and orange-filled bar [C and D]), defect of BCR leading to reduced antigen collection 
(blue lines [A and B] and blue-filled bar [C and D]), defect in antigen processing or presentation on peptide-MHC (cyan lines [A and B] and cyan-filled bar [C 
and D]), or increased apoptosis rate in the B cell subset positively selected by follicular T helper cells (green lines [A and B] and green-filled bar [C and D]). 
The GC phenotype is characterized by the total GC size (A), the number of output cells generated by one GC in the last hour (B), the fraction of high-affinity 
GC B cells at day 7 after immunization (C), and the fraction of apoptotic GC B cells at day 5 after immunization (D). All lines and bars are the mean of 50 
simulations. Standard deviations for A and B and time courses for C and D are provided in Supplemental Figure 4.
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the top diagonal gate indicates SWHEL B cells that carry BCRs with 
higher binding to HEL3X or HEL, respectively. In the same plots, 
the bottom gate corresponds to SWHEL B cells that carry BCRs with 
lower binding to HEL3x or HEL, respectively (18). In both cases, the 
higher ratio represents higher affinity. Based on the HEL3X stain-
ing, we observed decreased affinity maturation due to miR-155 
deficiency mainly in the LacZ+ LZ B cells (Figure 5C, left), which 
is consistent with increased apoptosis in this fraction (Figure 5B) 
and with previous reports showing impaired affinity maturation 
without miR-155 (13, 14). The HEL stain showed a similar pattern 
with higher differences between miR-155–sufficient and –deficient 
B cells (Figure 5C, right), again in accordance with published data. 
There are minor differences in the antigen-binding ratios between 
HEL3x and HEL, which is explained as follows. Immunization 
with HEL3x frequently leads to loss of HEL binding by the BCRs 
expressed by SWHEL B cells. As the response progresses, SWHEL B 
cells acquire higher affinity for HEL3x and thus are brightly stained 
with HEL3x (top diagonal gate in HEL3x staining), whereas the rest 
of SWHEL B cells are detected in the bottom diagonal gate (Figure 
5C). However, with HEL staining, SWHEL B cells that retain HEL 
binding are detected in the top diagonal gate, and the remainder of 
SWHEL B cells carrying high-affinity BCRs that bind to HEL3x or that 
results suggest that miR-155 provides survival signals mainly to 
c-MYC+ positively selected B cells, which is consistent with the 
highest levels of miR-155 expression on those cells. These results 
did not exclude a role for miR-155 in regulating the cell cycle. How-
ever, when we measured cell cycle dynamics in the 4 subsets in 
miR-155–sufficient or –deficient B cells, we detected no more than 
a small decrease in S-phase B cells in DZ LacZ+ Mir155–/– relative 
to their Mir155+/+ counterparts (Supplemental Table 1), suggesting 
that cell cycle regulation is not a major function of miR-155.
In the framework of the cyclic reentry model, we would predict 
that failure to provide survival signals to positively selected clones 
would impair affinity maturation. We tested affinity maturation in 
miR-155–deficient B cells according to DZ, LZ, and LacZ activity 8 
days after HEL3X-SRBC injection by staining with HEL3X and HEL 
(18). We chose this time point because, by this stage, affinity matu-
ration has started in this model system (22) and we can still detect 
miR-155–deficient GC B cells. As affinity maturation progresses, 
binding to HEL3X becomes brighter concomitant with a dimmer 
HEL-binding. Therefore, we assessed the ability of the BCR to bind 
HEL3X and HEL by calculating the ratio of high/low HEL3X–binding 
B cells (Figure 5C and Supplemental Figure 3) and the ratio of low/
high HEL–binding B cells. In the FACS plots shown in Figure 5C, 
Figure 7. The miR-155 target gene Jarid2 regulates the apoptosis of GC B cells. (A) SWHEL Mir155LacZ/+ or SWHEL Mir155LacZ/– B cells were adoptively transferred 
into CD45.1+ congenic recipients that were injected with HEL3X-SRBC. After 5 days, donor cells were sorted as described in Figure 2A. Jarid2 transcripts were 
measured by qPCR using Hprt for normalization. The mean ± SEM is presented from a representative data of 2 independent experiments (n = 6). *P < 0.05, 
***P < 0.001 using 1-way ANOVA followed by a Tukey’s multiple comparisons post-test. (B) SWHEL Mir155+/+ activated B cells were transduced with JARID2/
IRES-GFP virus or IRES-GFP control (empty vector). The GFP+ cells were sorted, and gene overexpression efficiency was evaluated by qPCR. The mean ± 
SEM of experiments is shown (n = 4) (left). Retrovirally transduced SWHEL B cells were adoptively transferred into HEL-SRBC–injected CD45.1
+ congenic mice 
(Supplemental Figure 5). Four days later, apoptosis was measured using AnnexinV and 7-AAD in GC HEL-binders split on the bases of GFP expression and 
DZ/LZ status as described in Supplemental Figure 6. The ratio of apoptosis was calculated as the relative values of the GFP+ to the GFP– counterparts to 
correct for potential biases across cultures. Data are pooled from 2 independent experiments and presented as the mean ± SEM. Each symbol represents 
a mouse. (C) The same method as B was used, except that activated SWHEL Mir155–/– B cells were retrovirally transduced with RNAi-JARID2/IRES-GFP or 
control vector, and Jarid2 silencing efficiency was evaluated by qPCR. Data are pooled from 2 independent experiments and presented as mean ± SEM. 
Each symbol represents a mouse. *P < 0.05, **P < 0.005 using two-tailed unpaired t test (B and C).
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JARID2 is a target of miR-155 in GC B cells. We next investigated 
whether JARID2 could be a miR-155 mediator. Mir155+/+-acti-
vated B cells were transduced with a JARID2-IRES-GFP–express-
ing retrovirus (~4-fold overexpression, Figure 7B) or a control 
virus expressing only GFP. In addition, Mir155–/–-activated B 
cells were transduced with an RNAi-JARID2-IRES-GFP expres-
sion (~3-fold reduced expression, Figure 7C) or GFP control. 
The retrovirally transduced B cells were adoptively transferred 
into HEL-SRBC–injected CD45.1+ congenic mice (Supplemental 
Figure 5), and apoptosis was measured in DZ and LZ B cells (Fig-
ure 7B, JARID2 overexpression; Figure 7C, JARID2 knockdown). 
Samples were normalized relative to the GFP– counterparts to 
correct for potential biases across cultures, although there were 
no statistically significant differences in the level of apoptosis 
of GFP– cells from control- or JARID2-transduced B cells (not 
shown). Ectopic expression of JARID2 in Mir155+/+ GC B cells 
significantly increased the percentage of AnnexinV+ cells in the 
LZ, and there is a trend of increased apoptosis in the DZ B cells, 
although it is not statistically significant at the 5% level (Figure 
7B). In contrast, reducing JARID2 expression in Mir155–/– GC B 
cells promoted the survival of DZ B cells but had not affected LZ 
B cell survival (Figure 7C). Taken together, these results suggest 
that JARID2 expression regulates the apoptosis of GC B cells in a 
miR-155–dependent manner.
Discussion
It has been known that miR-155 is required for GC function under 
physiological conditions (30); however, its precise mode of action 
remained unknown. Several lines of evidence in both mouse and 
human have indicated that miR-155 is expressed by a subset of 
GC B cells (13, 31). However, the exact GC B cell population that 
expresses miR-155 has been not identified. Here, we show that pos-
itively selected B cells express the highest levels of miR-155 within 
the GC. Previous work has identified BCL6 as a transcriptional 
repressor of miR-155 that ensures its shut-down in DZ B cells. 
Interestingly, BCL6 also represses c-MYC expression (10, 11), sug-
gesting that the 2 molecules may be cosuppressed when LZ B cells 
reenter the DZ. Whether c-MYC and miR-155 induction is coinci-
dental or one molecule precedes the other remains to be tested.
The in silico modeling of the GC supports our in vivo results 
showing that elevated apoptosis of positively selected GC B cells 
due to the Mir155 deletion is sufficient to explain the loss of cel-
lularity, reduced antibody secretion, and reduced affinity matu-
ration. The simulation results also suggest that the in vivo phe-
notype of miR-155–deficient mice may be caused by defective 
BCR signaling, which leads to decreased antigen uptake. How-
ever, while no reports so far show that miR-155 influences antigen 
uptake in B cells, we cannot exclude this possibility. Of interest, 
the in silico modeling also suggests that miR-155 may play a role 
in the initiation of the GC reaction. This is an area that needs 
further investigation but can also point toward synergy between 
c-MYC and miR-155, as c-MYC also plays a role in the initiation of 
the GC response (10, 11).
Our data suggest that JARID2 is one of the miR-155 targets 
that needs to be silenced in order to control apoptosis. As pre-
dicted, JARID2 overexpression in WT B cells increased the apop-
tosis of LZ B cells and, to a lesser extent, DZ B cells. However, its 
do not bind to either HEL3x or HEL with high affinity fall into the 
bottom diagonal gate. Taken together, our results suggest that miR-
155 expression is required for the survival of c-MYC+ LZ B cells and 
that failure of c-MYC+ LZ B cells to receive miR-155–dependent 
survival signals leads to decreased GC cellularity with concomitant 
impaired affinity maturation (Figure 5D).
In silico simulations are consistent with the hypothesis that miR-
155 regulates the survival of positively selected LZ B cells. To further 
substantiate our conclusions, we next asked whether the impaired 
survival of positively selected GC B cells would be sufficient to 
explain the complex phenotype of miR-155–deficient GC B cells, 
which includes a reduced GC size, a shorter duration of the GC 
reaction, reduced affinity maturation, and increased apoptosis of 
GC B cells. We extended the previously established mathematical 
model of the GC reaction (20) by affinity-dependent numbers of 
divisions (3, 23) and by antibody feedback (24), and we validated 
the model with WT data for GC population kinetics, plasma cell 
generation, affinity maturation, and apoptosis using in silico 
immunization with HEL3X or HEL (Figure 6, A–D, black lines and 
black-filled bar or gray dashed lines, respectively). Subsequently, 
different hypotheses for the effect of miR-155 deficiency were 
tested for their ability to reproduce the in vivo phenotype (Figure 
6, A–D, colored lines and bars). When the effect of miR-155 defi-
ciency was assumed to change division parameters, the in silico 
phenotype was in contradiction with the measured GC population 
kinetics (Figure 6, A–C, magenta, light green, orange lines and 
bars). This supports the in vivo result that miR-155 would not be a 
major regulator of the cell cycle (Supplemental Table 1). Similarly, 
a defect in peptide-MHC presentation was too weak to induce 
the observed fast shutdown of the GC reaction and thus unable 
to explain the phenotype (Figure 6, A–C, cyan lines and bars). 
However, when defective BCR signaling resulting in reduced anti-
gen uptake (Figure 6, A–D, and Supplemental Figure 4, blue lines 
and bars) or when increased apoptosis of the subset of positively 
selected GC B cells were considered (Figure 6, A–D, and Supple-
mental Figure 4, green lines and bars), we were able to qualitatively 
reproduce the phenotype observed in the in vivo experiment. This 
is quantitatively supported by the best agreement between these 2 
models and in vivo data (Supplemental Table 2). While the in silico 
results are consistent with the hypothesis that miR-155 regulates 
the survival of positively selected GC B cells, the in vivo data did 
not suffice to exclude or support a deregulation of BCR signaling.
The miR-155 target JARID2 regulates the apoptosis of GC B cells. 
The in silico modeling of the GC response showed that a 60% 
increase in the apoptosis of positively selected LZ B cells is suf-
ficient to explain the steady decrease in GC numbers and loss of 
affinity maturation due to miR-155 deficiency. One of the miR-
155 target genes that is consistently modulated by miR-155 is 
Jarid2 (12, 14, 15, 25, 26). JARID2 is a DNA-binding protein that 
belongs to the Jumonji (jmj) family (27) and has 2 miR-155 bind-
ing sites in its 3′-UTR (28, 29). As its downregulation by miR-155 
promotes the survival of chicken fibroblasts (28), we examined 
JARID2 expression in GC B cell subsets. In miR-155–sufficient 
B cells, Jarid2 mRNA was downregulated in the transition from 
the LZ LacZ– subset to the LZ LacZ+ subset (Figure 7A). However, 
miR-155–deficient B cells failed to downregulate Jarid2 mRNA in 
this transition (Figure 7A). This expression pattern suggests that 
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resemble LZ B cells according to the analyses of their gene-expres-
sion profiles (19). This is in agreement with our results showing low 
expression of miR-155 in the DZ and in most LZ GC B cells.
Collectively, we have shown that miR-155 expression is 
dynamically regulated in GC B cells. Only a small fraction of pro-
liferating positively selected c-MYC+ LZ B cells express the mature 
form of the miRNA. At the functional level, we observed that 
miR-155 expression protects c-MYC+ LZ B cells from apoptosis via 
JARID2, and thus it is critical for the maintenance of both the GC 
response and affinity maturation. We demonstrate the functional 
link between c-MYC and miR-155 in GC B cells, which may also 
be relevant to activated ABC-DLBCL. In the long-term, our results 
open up the possibility that blocking the functional interaction 
between miR-155 and c-MYC, by use of small inhibitors, may be a 
potential route for improved lymphoma therapy.
Methods
Mice. CD45.1+ congenic mice were bred and maintained in the Babra-
ham Research Campus small animal facility. miR-155–deficient mice, 
SWHEL mice, and Mycgfp/gfp mice have been described previously (12, 16, 
21). SWHEL mice were a gift from R. Brink (Garvan Institute of Medical 
Research/University of New South Wales), and Mycgfp/gfp mice were a 
gift from B.P. Sleckman (Washington University School of Medicine, 
St. Louis, Missouri, USA). miR-155–LacZ reporter mice (13) were pur-
chased from The Jackson Laboratory. All mice were maintained on the 
C57BL/6 background.
Adoptive transfer. SRBCs were conjugated to recombinant HEL 
(Sigma-Aldrich) or HEL3X (a gift from R. Brink [Garvan Institute 
of Medical Research/University of New South Wales]) with 1-eth-
yl-3-(3-dimethylaminopropyl) carbodiimide hydrochloride (Sigma-Al-
drich) as previously described (49). CD45.2+ spleen B cells from SWHEL 
donor mice were purified using mouse B cell Isolation Kit (Miltenyi 
Biotec). HEL-binding B cells (5 × 104) were i.v. injected into CD45.1+ 
congenic recipients, followed by injection with 2 × 108 SRBC conju-
gated to a specific recombinant HEL protein. For analyses, CD45.2+ 
donor splenocytes were enriched by CD45.1 negative selection using 
an autoMACS pro separator (Miltenyi Biotec).
Immunohistology. Splenic cryosections were fixed in acetone and 
blocked with 30% normal horse serum. HEL-binding cells were detected 
by incubation with 100 ng/ml HEL followed by polyclonal rabbit anti-
HEL serum and goat anti–rabbit IgG-FITC (Southern Biotechnology 
Associates). T cells were stained with anti–CD3 biotin (clone 500A2, 
eBioscience) followed by streptavidin Alexa Fluor 550 (Invitrogen), and 
follicular B cells with anti–IgD 647 (clone 11-26c.2a, BD Biosciences). 
Slides were analyzed using a Zeiss Axiovert 200M microscope with a 
×10 objective and processed using Adobe Photoshop software.
Flow cytometry and cell sorting. Multicolor flow cytometry for anal-
yses or for sorting was performed on a LSR Fortessa or FACSAria (BD 
Biosciences), respectively. Single cell suspensions of splenocytes were 
blocked with anti-CD16/32 mAb (clone 2.4G2, in house), and followed 
by staining with the following antibodies: anti-B220 (clone RA3-6B2), 
anti-CD38 (clone 90), anti-CD45.2 (clone 104), anti-CXCR4 (clone 
2B11), and AA4.1, from eBioscience; anti-CD86 (clone GL1, BioLeg-
end); and anti-CD95 (clone Jo2) and anti-IgG1 (clone A85-1), from BD 
Biosciences. HEL-binding B cells were stained as described previously 
(17). LacZ activity was visualized using the FluoReporter-LacZ-Flow 
cytometry kit (Invitrogen). For cell cycle analyses, cells of each sorted 
downregulation in miR-155–deficient B cells only promoted the 
survival of DZ B cells. Although we achieved 60% JARID2 knock-
down in cultured B cells, we cannot assume that JARID2 silenc-
ing is equally efficient in vivo. Alternatively, ectopically silenced 
JARID2 in a subset of LZ B cells that highly express JARID2 in the 
miR-155–sufficient background (e.g., LZ LacZ–, Figure 7A) may 
have caused deleterious effects on cell survival. JARID2 regu-
lates cell proliferation and differentiation in several tissues (27, 
32, 33), and recent reports have shown that JARID2 is a part of 
polycomb repressive complex 2 (PRC2) (32, 34, 35). Excessively 
low expression of JARID2 in these GC B cells may have disturbed 
PRC2 recruitment to its targets, including survival/apoptosis-re-
lated genes (36). In this scenario, the protective survival effect 
conferred by lowering JARID2 in LZ LacZ+ B cells may have been 
diluted or became undetectable. Disentangling this issue would 
require generating mice carrying Jarid2 alleles unresponsive 
to miR-155. The identity of JARID2 target genes in GC B cells 
and whether JARID2 function in GC B cells is PRC2 dependent 
remains unknown. It also remains unknown whether targets of 
miR-155, in addition to JARID2, are important in the regulation of 
apoptosis in c-MYC+ GC B cells.
Expression of c-MYC in positively selected GC B cells is essen-
tial to maintain the GC response, although its role is uncertain. 
c-MYC regulates a large quantity of transcription of genes and thus 
controls cell growth and proliferation; however, this molecule also 
functions to sensitize cells to apoptosis (37–39). We showed that 
miR-155 expression in GC B cells mainly protect c-MYC+ positively 
selected LZ B cells from apoptosis and, to a lesser extent, c-MYC+ 
DZ B cells. Given these results, we suggest that miR-155 mitigates 
the proapoptotic effects caused by c-MYC in positively selected 
GC B cells, and thus, we provide a basis for functional coopera-
tion between c-MYC and miR-155 in the normal course of the GC 
reaction. Understanding the physiology of the GC response also 
informs on B cell lymphomagenesis. Although miR-155 host tran-
script BIC and c-MYC have been shown to cooperate in promoting 
cellular transformation using the chicken system (40, 41), how 
these molecules achieve this has been unknown for a long time. 
The functional interaction between c-MYC and miR-155 we show 
here may explain the longstanding enigma of the 2 cooperating 
oncogenes: high expression of miR-155 provides extra survival 
advantage to transformed c-MYC+ cells. Interestingly, c-MYC 
acquires the ability to bind to regulatory elements of Jarid2 upon 
initiation of cellular transformation and concomitantly inhibits its 
expression (42). Thus, it is possible that one of the points of molec-
ular convergence between miR-155 and c-MYC is JARID2 and that 
repression of this molecule by both miR-155 and c-MYC may be 
required for survival of transformed B cells. In fact, this regulation 
may also be relevant to activated B cell–like diffuse large B cell 
lymphoma cells (ABC-DLBCL), as ABC-DLBCL cells overexpress 
both c-MYC (43–45) and miR-155 (46, 47).
ABC-DLBCL resembles post–GC B cells that are blocked in 
their process of differentiation toward plasma cells (48). Given that 
positively selected GC B cells are enriched in plasmablast progeni-
tors (4) and express high levels of miR-155 and c-MYC, these cells 
may represent the normal counterpart of ABC-DLBCL. In contrast, 
low expression of miR-155 has been reported in another DLBCL 
subtype, GCB-DLBCL, and Burkitt’s lymphoma, both of which 
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Statistics. Statistical analyses were performed by a 2-tailed 
unpaired Student’s t test in Microsoft Excel or 1-way ANOVA test for 
multiple group comparisons followed by a Tukey’s multiple compar-
isons post-test in GraphPad Prism software. A P value less than 0.05 
was considered statistically significant.
Study approval. All animal procedures complied with UK Home 
Office regulations (London, United Kingdom) and EU Directive 
2010/63/EU (European Union, Brussels, Belgium) and were approved 
by the Babraham Research Campus Animal Welfare, Experimentation 
and Ethics Committee (Cambridge, United Kingdom).
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subset containing more than 5 × 104 cells were fixed and permeabilized 
using a Cytofix/Cytoperm Kit (BD Biosciences), followed by staining 
with 10 μg/ml DAPI. Cell cycle was calculated by FlowJo Dean/Jett/
Fox algorithms. To quantify protein expression, we used the gMFI to 
account for the log-normal behavior of flow data. The data were ana-
lyzed with FlowJo software (Tree Star).
qPCR. Relative quantifications of gene expression were deter-
mined by Hprt expression. Single cells were directly sorted into 
96-well plates containing 5 μl water and 25 ng carrier RNA (QIAGEN) 
per well. miR-155 and U6 were reverse transcribed with Super Script 
III (Invitrogen) and Taqman MicroRNA assay set (Applied Biosys-
tems). The primers used for Bcl6 were 5′-CAGCAACATCTACTC-
GCCCAA-3′ and 5′-ATGGAGCATTCCGAGCAGAAG-3′; the remain-
der of the primers were as described elsewhere: Prdm1 (50), Aicda (15), 
Myc (11), and Jarid2 (32).
Retroviral transduction of B cells. Mouse Jarid2 cDNA (Thermo Sci-
entific) and JARID2-specific RNAi oligonucleotide (32) were subcloned 
into the pMigRI-IRES-GFP vector. Retroviral vectors were introduced 
into Plat-E packaging cells, and retroviral supernatants were collected 
48 hours after transfection. For B cell activation, SWHEL mice were i.p. 
injected with 4 mg HEL, and after 6 hours, mice were sacrificed and 
spleens were collected. B cells were cultured in RPMI supplemented with 
10% FBS, 2 mM GlutaMAX (Invitrogen), 50 U/ml penicillin, 50 μg/ml 
streptomycin, and 50 μM 2-ME in the presence of 1 μg/ml anti-CD40 
(clone HM40-3, eBioscience) for 16 hours before spin infection. Twen-
ty-eight to 30 hours after infection, the cells were adoptively transferred 
into CD45.1+ congenic recipients that had been i.p. injected with 2 × 108 
HEL-SRBC 30 hours earlier.
Mathematical model. For mathematical modeling of the GC reac-
tion, an agent-based model combined with a model for soluble anti-
bodies was employed (20, 24). The model was validated with WT data 
and then used to simulate different hypothetical effects of miR-155. 
The first data point of WT mice immunized with HEL or with HEL3X 
determined the time of GC onset after immunization. The best fit was 
achieved by GC onset 2 days after immunization with HEL and 2 days 
and 8 hours after immunization with HEL3X. The parameters used were 
the result of various test runs and represent the best choice in terms of 
RSS values (see Supplemental Table 2) for each of the miR-155 impact 
points. Each simulation was repeated 50 times. The mean time course 
is shown in Figure 6, and the standard deviation for the best solutions is 
represented in Supplemental Figure 4.
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